MENINGIOMA publications
Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1
Sievers P, Sill M, Blume C, et al.
Acta Neuropathol. 2020;10.1007/s00401-020–02247‑2. doi:10.1007/s00401-020–02247‑2
https://link.springer.com/article/10.1007/s00401-020–02247‑2
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas
Sievers P, Hielscher T, Schrimpf D, et al.
Acta Neuropathologica 2020;10.1007/s00401-020–02188‑w. doi:10.1007/s00401-020–02188‑w
https://link.springer.com/article/10.1007%2Fs00401-020–02188‑w
YAP1-fusions in pediatric NF2-wildtype meningioma
Sievers P, Chiang J, Schrimpf D, et al.
Acta Neuropathol. 2020;10.1007/s00401-Acta Neuropathologica 2019;10.1007/s00401-019–02095‑9. doi:10.1007/s00401-019–02095‑9
https://link.springer.com/article/10.1007/s00401-019–02095‑9
Mutational patterns and regulatory networks in epigenetic subgroups of meningioma
Paramasivam N, Hübschmann D, Toprak U, et al.
Acta Neuropathologica 2019;10.1007/s00401-019–02008‑w. doi:10.1007/s00401-019–02008‑w
https://link.springer.com/article/10.1007%2Fs00401-019–02008‑w
Identification of KIF11 As a Novel Target in Meningioma
Jungwirth G, Yu T, Moustafa M, et al.
Cancers 2019;10.3390/cancers11040545. doi:10.3390/cancers11040545
Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas
Rapp C, Dettling S, Liu F, et al.
Clinical Cancer Research 2019;10.1158/1078–0432.CCR-19–0389. doi:10.1158/1078–0432.CCR-19–0389
https://clincancerres.aacrjournals.org/content/25/17/5260.long
Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT
Jungwirth G, Warta R, Beynon C, et al.
Acta Neuropatologica Communications 2019;10.1186/s40478-019‑0793‑4. doi:10.1186/s40478-019‑0793‑4
https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-019‑0793‑4
Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p
Sievers P, Stichel D, Hielscher T, et al.
Acta Neuropathologica 2018;10.1007/s00401-018‑1924‑x. doi:10.1007/s00401-018‑1924‑x
https://link.springer.com/article/10.1007%2Fs00401-018‑1924‑x
Crispr/Cas-based modeling of NF2 loss in meningioma cells
Waldt N, Kesseler C, Fala P, et al.
Journal of Neuroscience Methods 356 (2021);10.1016/j.jneumeth.2021.109141.doi:10.1016/j.jneumeth.2021.109141
https://www.sciencedirect.com/science/article/pii/S0165027021000765?via%3Dihub
KLF4K409Q–mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment
von Spreckelsen N, Waldt N, Poetschke R, et al.
Acta Neuropathologica Communications 2020;10.1186/s40478-020–00912‑x. doi.org/10.1186/s40478-020–00912‑x
https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-020–00912‑x
MENINGIOMA preliminary work
2018: Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence
Katz L, Hielscher T, Liechty B, et al.
Acta Neuropathologica 2018;10.1007/s00401-018‑1844‑9. doi:10.1007/s00401-018‑1844‑9
https://link.springer.com/article/10.1007%2Fs00401-018‑1844‑9
2017: Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence
Yesilöz Ü, Kirches E, Hartmann C, et al.
Neuro-Oncology 2017;10.1093/neuonc/nox018. doi:10.1093/neuonc/nox018
https://academic.oup.com/neuro-oncology/article/19/8/1088/3800501
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
Sahm F, Schrimpf D, Stichel D, et al.
The Lancet Oncology 2017;10.1016/S1470-2045(17)30155–9. doi:10.1016/S1470-2045(17)30155–9
https://www.sciencedirect.com/science/article/pii/S1470204517301559?via%3Dihub
Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363
Weller M, Roth P, Sahm F, et al.
Journal of the National Cancer Institute 2017;10.1093/jnci/djw320. doi:10.1093/jnci/djw320
Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature
Sahm F, Toprak U, Hübschmann D, et al.
Acta Neuropathologica 2017;10.1007/s00401-017‑1715‑9. doi:10.1007/s00401-017‑1715‑9
https://link.springer.com/article/10.1007%2Fs00401-017‑1715‑9
Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade
Schmidt M, Mock A, Jungk C, et al.
Oncotarget. 2016;10.18632/oncotarget.7396. doi:10.18632/oncotarget.7396
TERT Promoter Mutations and Risk of Recurrence in Meningioma
Sahm F, Schrimpf D, Olar A, et al.
Journal of the national cancer Institute 2015;10.1093/jnci/djv377. doi:10.1093/jnci/djv377